ZOSTER VACCINE, LIVE, (OKA/MERCK)
Postherpetic Neuralgia
US Department of Veterans AffairsvaccinePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Postherpetic Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE Seoul National University Hospital | Phase 4 | BBB |
Capsaicin Astellas Pharma Europe Ltd. | Phase 4 | BBB |
Pregabalin Neurodawn Pharmaceutical Co., Ltd. | Phase 4 | BBB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- University of Medicine and Pharmacy at Ho Chi Minh City | Phase 4 | BBB |
Capsaicin Astellas Pharma Europe Ltd. | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
ZOSTER VACCINE, LIVE, (OKA/MERCK) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →